Stevanato Group (STVN) shares jump after 2026 outlook leans on GLP-1 drug packaging
Stevanato Group S.p.A. rolled out its inaugural 2026 guidance Wednesday, eyeing revenue between €1.26 billion and €1.29 billion and projecting adjusted EBITDA in the €331.8 million to €346.9 million range. That figure strips out interest, taxes, depreciation, amortization and certain other items. The Italian drug-packaging firm noted GLP-1 products—used for diabetes and weight management—accounted for roughly 19% to 20% of 2025 revenue, which climbed 7% to €1.186 billion. Guidance is under scrutiny these days, as packaging is now a sticking point for injectable drugs—think vaccines or the current obesity and diabetes therapies. Drugmakers are pushing for more ready-to-use parts to keep filling lines running and sidestep production halts.